CL2012001176A1 - Compuestos derivados de bencimidazol-imidazol, inhibidores del virus de la hepatitis c (hcv); composición farmacéutica que los comprende; combinación farmacéutica; uso en la prevención o tratamiento de infección de hcv. - Google Patents

Compuestos derivados de bencimidazol-imidazol, inhibidores del virus de la hepatitis c (hcv); composición farmacéutica que los comprende; combinación farmacéutica; uso en la prevención o tratamiento de infección de hcv.

Info

Publication number: CL2012001176A1
Authority: CL; Chile
Prior art keywords: hcv; benzimidazole; hepatitis; virus; inhibitors
Prior art date: 2009-11-04

Application number

CL2012001176A

Other languages

English (en)

Inventor

Stefaan Julien Last

Koen Vandyck

Ionnis Nicolaos Houpis

Pierre Jean Marie Bernard Raboisson

Original Assignee

Janssen R&D Ireland

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-11-04

Filing date

2012-05-04

Publication date

2012-08-31

2012-05-04 Application filed by Janssen R&D Ireland filed Critical Janssen R&D Ireland

2012-08-31 Publication of CL2012001176A1 publication Critical patent/CL2012001176A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CL2012001176A 2009-11-04 2012-05-04 Compuestos derivados de bencimidazol-imidazol, inhibidores del virus de la hepatitis c (hcv); composición farmacéutica que los comprende; combinación farmacéutica; uso en la prevención o tratamiento de infección de hcv. CL2012001176A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP09175015		2009-11-04
EP10154583		2010-02-24

Publications (1)

Publication Number	Publication Date
CL2012001176A1 true CL2012001176A1 (es)	2012-08-31

Family

ID=43266424

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2012001176A CL2012001176A1 (es)	2009-11-04	2012-05-04	Compuestos derivados de bencimidazol-imidazol, inhibidores del virus de la hepatitis c (hcv); composición farmacéutica que los comprende; combinación farmacéutica; uso en la prevención o tratamiento de infección de hcv.

Country Status (23)

Country	Link
US (3)	US9427428B2 (es)
EP (1)	EP2496572A1 (es)
JP (1)	JP6005515B2 (es)
KR (1)	KR20120091292A (es)
CN (1)	CN102741241B (es)
AP (1)	AP2012006216A0 (es)
AR (1)	AR078888A1 (es)
AU (1)	AU2010317085A1 (es)
BR (1)	BR112012010502A2 (es)
CA (1)	CA2780034C (es)
CL (1)	CL2012001176A1 (es)
CO (1)	CO6531445A2 (es)
CR (1)	CR20120302A (es)
EA (1)	EA022839B1 (es)
EC (1)	ECSP12011867A (es)
IL (1)	IL219087A0 (es)
MX (1)	MX2012005178A (es)
PH (1)	PH12012500752A1 (es)
TW (1)	TW201127378A (es)
UA (1)	UA108211C2 (es)
UY (1)	UY32997A (es)
WO (1)	WO2011054834A1 (es)
ZA (1)	ZA201203205B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN104163816A (zh)	2008-12-03	2014-11-26	普雷西迪奥制药公司	Hcv ns5a的抑制剂
MX2011006332A (es)	2008-12-23	2011-06-27	Abbott Lab	Compuestos antivirales.
JP2012513410A (ja)	2008-12-23	2012-06-14	アボット・ラボラトリーズ	抗ウイルス化合物
US8394968B2 (en)	2009-02-17	2013-03-12	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
KR20130130875A (ko)	2009-02-27	2013-12-02	이난타 파마슈티칼스, 인코포레이티드	Ｃ형 간염 바이러스 억제제
US8796466B2 (en)	2009-03-30	2014-08-05	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
TW201038559A (en)	2009-04-09	2010-11-01	Bristol Myers Squibb Co	Hepatitis C virus inhibitors
US8143414B2 (en)	2009-04-13	2012-03-27	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
EP2419404B1 (en)	2009-04-15	2015-11-04	AbbVie Inc.	Anti-viral compounds
MX363732B (es)	2009-05-13	2019-04-01	Gilead Pharmasset Llc Star	Compuestos antivirales.
US8138215B2 (en)	2009-05-29	2012-03-20	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8211928B2 (en)	2009-05-29	2012-07-03	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US9394279B2 (en)	2009-06-11	2016-07-19	Abbvie Inc.	Anti-viral compounds
US8937150B2 (en)	2009-06-11	2015-01-20	Abbvie Inc.	Anti-viral compounds
DK2368890T3 (da)	2009-06-11	2013-07-22	Abbvie Bahamas Ltd	Hepatitis C-virusinhibitorer
US8716454B2 (en)	2009-06-11	2014-05-06	Abbvie Inc.	Solid compositions
US20110274648A1 (en) *	2009-11-11	2011-11-10	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
US20110269956A1 (en)	2009-11-11	2011-11-03	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
US20110281910A1 (en)	2009-11-12	2011-11-17	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
US8377980B2 (en)	2009-12-16	2013-02-19	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8362020B2 (en)	2009-12-30	2013-01-29	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
PE20130244A1 (es)	2010-01-25	2013-03-10	Enanta Pharm Inc	Inhibidores del virus de la hepatitis c
US8933110B2 (en)	2010-01-25	2015-01-13	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
WO2011127350A1 (en)	2010-04-09	2011-10-13	Enanta Pharmaceuticals, Inc.	Hepatitis c virus inhibitors
CA2800509A1 (en)	2010-05-24	2011-12-01	Presidio Pharmaceuticals, Inc.	Inhibitors of hcv ns5a
EP2575819A4 (en)	2010-06-04	2013-11-27	Enanta Pharm Inc	INHIBITORS OF HEPATITIS C VIRUS
NZ605440A (en)	2010-06-10	2014-05-30	Abbvie Bahamas Ltd	Solid compositions comprising an hcv inhibitor
US8697704B2 (en)	2010-08-12	2014-04-15	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8552047B2 (en)	2011-02-07	2013-10-08	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US9243025B2 (en) *	2011-03-31	2016-01-26	Idenix Pharmaceuticals, Llc	Compounds and pharmaceutical compositions for the treatment of viral infections
US9546160B2 (en)	2011-05-12	2017-01-17	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US10201584B1 (en)	2011-05-17	2019-02-12	Abbvie Inc.	Compositions and methods for treating HCV
CA2840242C (en)	2011-09-16	2019-03-26	Gilead Sciences, Inc.	Methods for treating hcv
JP6199891B2 (ja) *	2011-12-28	2017-09-20	ヤンセン・サイエンシズ・アイルランド・ユーシー	Ｈｃｖ阻害剤としてのキナゾリノン誘導体
US9034832B2 (en)	2011-12-29	2015-05-19	Abbvie Inc.	Solid compositions
US9326973B2 (en)	2012-01-13	2016-05-03	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
KR20140145126A (ko) *	2012-02-13	2014-12-22	프레시디오 파마슈티칼스, 인코포레이티드	Hcv ns5a의 저해제를 포함하는 고체형태, 이의 조성물 및 이에 의한 용도
CN102796084A (zh) *	2012-09-10	2012-11-28	合肥科尚医药科技有限公司	一种活性物质及其在治疗丙型肝炎中的应用及制备方法
KR20200060782A (ko)	2013-01-31	2020-06-01	길리애드 파마셋 엘엘씨	두 항바이러스 화합물의 병용 제형물
US11484534B2 (en)	2013-03-14	2022-11-01	Abbvie Inc.	Methods for treating HCV
US20150023913A1 (en)	2013-07-02	2015-01-22	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
US9717712B2 (en)	2013-07-02	2017-08-01	Bristol-Myers Squibb Company	Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
WO2015009744A1 (en)	2013-07-17	2015-01-22	Bristol-Myers Squibb Company	Combinations comprising biphenyl derivatives for use in the treatment of hcv
EP3650014B1 (en)	2013-08-27	2021-10-06	Gilead Pharmasset LLC	Combination formulation of two antiviral compounds
WO2015103490A1 (en)	2014-01-03	2015-07-09	Abbvie, Inc.	Solid antiviral dosage forms
WO2015187818A1 (en) *	2014-06-03	2015-12-10	The Arizona Board Of Regents On Behalf Of The University Of Arizona	Benzimidazole analogues and related methods
TWI721947B (zh)	2014-06-11	2021-03-21	美商基利法瑪席特有限責任公司	抗病毒化合物的固態形式
TWI679203B (zh) *	2014-06-11	2019-12-11	美商基利法瑪席特有限責任公司	製備抗病毒化合物之方法
US20160375017A1 (en)	2015-06-26	2016-12-29	Abbvie Inc.	Solid Pharmaceutical Compositions for Treating HCV
US10617675B2 (en)	2015-08-06	2020-04-14	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
CA3220903A1 (en)	2021-05-21	2022-11-24	Gilead Sciences, Inc.	Pentacyclic derivatives as zika virus inhibitors
CN116462622B (zh) *	2023-03-10	2024-02-09	上海药坦药物研究开发有限公司	一种N-Boc-L-脯氨醛的制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4213765A (en)	1979-01-02	1980-07-22	Union Carbide Corporation	Oxidative coal desulfurization using lime to regenerate alkali metal hydroxide from reaction product
US5807876A (en)	1996-04-23	1998-09-15	Vertex Pharmaceuticals Incorporated	Inhibitors of IMPDH enzyme
US6054472A (en)	1996-04-23	2000-04-25	Vertex Pharmaceuticals, Incorporated	Inhibitors of IMPDH enzyme
IL126674A (en)	1996-04-23	2005-08-31	Vertex Pharma	Use of cyclic and heterocyclic compounds for preparing pharmaceutical compositions inhibiting impdh activity, pharmaceutical compositions containing the same and novel thiazole and oxazole urea derivatives
ATE244717T1 (de)	1997-03-14	2003-07-15	Vertex Pharma	Inhibitoren des impdh-enzyms
EP1964561A1 (en)	1999-03-19	2008-09-03	Vertex Pharmaceuticals Incorporated	Inhibitors of IMPDH enzyme
SV2003000617A (es)	2000-08-31	2003-01-13	Lilly Co Eli	Inhibidores de la proteasa peptidomimetica ref. x-14912m
AU2003298839A1 (en)	2002-12-03	2004-06-23	Isis Pharmaceuticals, Inc.	Benzimidazoles and analogs thereof as antivirals
US8143288B2 (en)	2005-06-06	2012-03-27	Bristol-Myers Squibb Company	Inhibitors of HCV replication
US7659270B2 (en)	2006-08-11	2010-02-09	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8329159B2 (en) *	2006-08-11	2012-12-11	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
AU2007313250A1 (en)	2006-10-13	2008-04-24	Xtl Biopharmaceuticals Ltd	Compounds and methods for treatment of HCV
WO2008070447A2 (en)	2006-11-21	2008-06-12	Smithkline Beecham Corporation	Anti-viral compounds
NZ587323A (en)	2008-02-12	2012-02-24	Bristol Myers Squibb Co	Hepatitis c virus inhibitors
JP5312486B2 (ja)	2008-02-13	2013-10-09	ブリストル−マイヤーズスクイブカンパニー	Ｃ型肝炎ウイルス阻害剤
US7704992B2 (en)	2008-02-13	2010-04-27	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
TWI454476B (zh) *	2008-07-08	2014-10-01	Tibotec Pharm Ltd	用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
US7906655B2 (en) *	2008-08-07	2011-03-15	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
WO2010065681A1 (en)	2008-12-03	2010-06-10	Presidio Pharmaceuticals, Inc.	Inhibitors of hcv ns5a
CN104163816A (zh) *	2008-12-03	2014-11-26	普雷西迪奥制药公司	Hcv ns5a的抑制剂
PL2378883T3 (pl) *	2008-12-04	2016-06-30	Intec Pharma Ltd	SYSTEM DOSTARCZANIA LEKU ZATRZYMYWANEGO W ŻOŁĄDKU dLA ZALEPLONU
EP2393359A4 (en) *	2009-02-09	2012-10-03	Enanta Pharm Inc	COMPOUND DIBENZIMIDAZOLE DERIVATIVES
TWI438200B (zh) *	2009-02-17	2014-05-21	必治妥美雅史谷比公司	Ｃ型肝炎病毒抑制劑
CA2753313A1 (en) *	2009-02-23	2010-08-26	Presidio Pharmaceuticals, Inc.	Inhibitors of hcv ns5a
KR20130130875A (ko) *	2009-02-27	2013-12-02	이난타 파마슈티칼스, 인코포레이티드	Ｃ형 간염 바이러스 억제제
US8101643B2 (en) *	2009-02-27	2012-01-24	Enanta Pharmaceuticals, Inc.	Benzimidazole derivatives
MX363732B (es)	2009-05-13	2019-04-01	Gilead Pharmasset Llc Star	Compuestos antivirales.
EP2435424B1 (en) *	2009-05-29	2015-01-21	Merck Sharp & Dohme Corp.	Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c

2010
- 2010-03-11 UA UAA201204598A patent/UA108211C2/uk unknown
- 2010-11-03 WO PCT/EP2010/066668 patent/WO2011054834A1/en not_active Ceased
- 2010-11-03 EA EA201290260A patent/EA022839B1/ru not_active IP Right Cessation
- 2010-11-03 TW TW099137712A patent/TW201127378A/zh unknown
- 2010-11-03 EP EP10771766A patent/EP2496572A1/en not_active Withdrawn
- 2010-11-03 PH PH1/2012/500752A patent/PH12012500752A1/en unknown
- 2010-11-03 AU AU2010317085A patent/AU2010317085A1/en not_active Abandoned
- 2010-11-03 BR BR112012010502A patent/BR112012010502A2/pt not_active IP Right Cessation
- 2010-11-03 JP JP2012537376A patent/JP6005515B2/ja not_active Expired - Fee Related
- 2010-11-03 AP AP2012006216A patent/AP2012006216A0/xx unknown
- 2010-11-03 CN CN201080050509.7A patent/CN102741241B/zh not_active Expired - Fee Related
- 2010-11-03 UY UY0001032997A patent/UY32997A/es unknown
- 2010-11-03 CA CA2780034A patent/CA2780034C/en not_active Expired - Fee Related
- 2010-11-03 US US13/508,186 patent/US9427428B2/en not_active Expired - Fee Related
- 2010-11-03 MX MX2012005178A patent/MX2012005178A/es not_active Application Discontinuation
- 2010-11-03 KR KR1020127014503A patent/KR20120091292A/ko not_active Withdrawn
- 2010-11-04 AR ARP100104084A patent/AR078888A1/es not_active Application Discontinuation
2012
- 2012-04-05 IL IL219087A patent/IL219087A0/en unknown
- 2012-04-13 CO CO12061178A patent/CO6531445A2/es not_active Application Discontinuation
- 2012-05-03 ZA ZA2012/03205A patent/ZA201203205B/en unknown
- 2012-05-04 EC ECSP12011867 patent/ECSP12011867A/es unknown
- 2012-05-04 CL CL2012001176A patent/CL2012001176A1/es unknown
- 2012-06-04 CR CR20120302A patent/CR20120302A/es unknown
2013
- 2013-03-15 US US13/836,816 patent/US9433609B2/en not_active Expired - Fee Related
2016
- 2016-08-04 US US15/228,720 patent/US20160340344A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN102741241B (zh)	2015-05-20
CO6531445A2 (es)	2012-09-28
US20120219594A1 (en)	2012-08-30
EA201290260A1 (ru)	2013-12-30
UA108211C2 (uk)	2015-04-10
CA2780034A1 (en)	2011-05-12
IL219087A0 (en)	2012-06-28
UY32997A (es)	2011-05-31
AP2012006216A0 (en)	2012-04-30
EP2496572A1 (en)	2012-09-12
US9427428B2 (en)	2016-08-30
CR20120302A (es)	2012-10-25
ZA201203205B (en)	2014-10-29
JP6005515B2 (ja)	2016-10-12
AR078888A1 (es)	2011-12-07
US20160340344A1 (en)	2016-11-24
EA022839B1 (ru)	2016-03-31
ECSP12011867A (es)	2012-10-30
CN102741241A (zh)	2012-10-17
MX2012005178A (es)	2012-06-08
JP2013510119A (ja)	2013-03-21
KR20120091292A (ko)	2012-08-17
WO2011054834A1 (en)	2011-05-12
BR112012010502A2 (pt)	2016-03-15
CA2780034C (en)	2018-04-10
PH12012500752A1 (en)	2013-01-07
TW201127378A (en)	2011-08-16
US20140107172A1 (en)	2014-04-17
US9433609B2 (en)	2016-09-06
AU2010317085A1 (en)	2012-05-10

Similar Documents

Publication	Publication Date	Title
CL2012001176A1 (es)	2012-08-31	Compuestos derivados de bencimidazol-imidazol, inhibidores del virus de la hepatitis c (hcv); composición farmacéutica que los comprende; combinación farmacéutica; uso en la prevención o tratamiento de infección de hcv.
CL2013000727A1 (es)	2013-08-23	Compuestos derivados de nucleosidos de imidazo[1,2-f][1,2,4]triazinilo; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion por virus flaviviridae, particularmente infecciones por el virus de la hepatitis c.
CL2007003250A1 (es)	2008-05-23	Compuestos derivados de isoquinolina, inhibidores del virus de hepatitis c; composicion farmaceutica; y uso para el tratamiento de una infeccion por vhc.
CL2013001141A1 (es)	2013-10-04	Compuestos derivados de heterociclos condensados, inhibidores del virus de la hepatitis c; composicion farmaceutica que los contiene; y su uso para el tratamiento de la infeccion por el virus de la hepatitis c.
CL2012000573A1 (es)	2012-08-31	Compuestos derivados de bifenil-pirrolidinil-imidazol; composicion farmaceutica que los comprende; su uso en el tratamiento de una infeccion viral por hcv.
CL2011002830A1 (es)	2012-03-23	Compuestos derivados de haloalquil heteroaril benzamidas; composicion farmaceutica uso de la composicion en el tratamiento de una infeccion viral, tal como el virus de la hepatitis b y c.
CL2007003299A1 (es)	2008-08-22	Compuestos derivados de macrociclos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
CL2013003360A1 (es)	2014-07-04	“compuestos derivados de 4-aril-n-[3-(sulfonimidoil)fenil]-1,3,5-triazin-2-amina sustituidos, inhibidores cdk; compuestos intermediarios, composición y combinación farmacéutica que los comprende; y su uso en el tratamiento de enfermedades hiperproliferativas, infecciosas inducidas por virus y/o cardiovasculares”. pct
CL2013001339A1 (es)	2014-03-07	Compuestos derivados heterociclicos condensados, con actividad antiviral; composicion farmaceutica que los comprende; y su uso para la prevencion o tratamiento de la infeccion de vih.
ECSP17064986A (es)	2017-10-31	Compuestos antivirales
BRPI1013394A2 (pt)	2016-06-21	"composto, composição farmacêutica, uso do composto, e, método para tratar um paciente infectado com virus da hepatite c."
CL2007003686A1 (es)	2008-06-27	Compuestos derivados de indol con anillo unido en las posiciones 4,5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para tratar una infeccion viral.
CL2008001005A1 (es)	2008-10-17	Compuestos derivados de azufre, inhibidores de la serina proteasa ns3 del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos asociados a la proteasa de hcv.
CL2013002939A1 (es)	2014-07-04	Compuestos derivados de nucleosidos 2´-sustituidos , inhibidores ns5a; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
CL2009000305A1 (es)	2010-02-19	Compuestos derivados de 2-aril-sustituido-1-benzofurano-3-carboxamida, inhibidores de la polimerasa ns5b; composicion farmaceutica; y su uso en el tratamiento de una enfermedad causada por el virus de la hepatitis c (hcv).
CL2010001634A1 (es)	2011-08-05	Compuestos derivados de nucleosidos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que los comprende; y combinacion farmaceutica.
BRPI0916235A2 (pt)	2018-03-13	composto, composição farmacêutica, uso do composto ou da composição, e, método para tratar um paciente infectado com hcv
CL2012002489A1 (es)	2012-11-30	Compuestos derivados de sililo nafto-imidazol; composición farmacéutica; y su uso para prevenir o tratar una infección por el virus de la hepatitis c.
CL2013001428A1 (es)	2014-06-27	Compuesto que inhibe la actividad del virus de la hepatitis c (hcv); composición farmacéutica que comprende el compuesto; método de tratamiento de hepatitis c.
CL2008003511A1 (es)	2010-02-19	Compuestos derivados nucleotidicos, inhibidores de polimerasa ns5b del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
ECSP10010413A (es)	2010-11-30	Inhibidores macrociclicos de serina proteasa
CL2015000487A1 (es)	2015-06-12	Compuestos derivados de sulfamoilarilamidas; composicion farmaceutica que los comprende, util para la prevencion o tratamiento de una infeccion por el virus de la hepatitis b (vhb).
CL2014000612A1 (es)	2014-09-05	Compuestos derivados de prolinas macrociclicas, inhibidores de las proteasas de serina del virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; y su uso para tratar una infeccion viral tal como la infeccion por el virus de la hepatitis c (vhc).
CL2012000147A1 (es)	2012-09-07	Compuestos derivados del acido 5-etinil-3(formilamino) tiofeno-2-carboxilico, inhibidores de los virus de la familia flaviviridae; composicion farmaceutica que comprende un compuesto; y su uso de los compuestos en la preparacion de medicamentos.
CL2013003229A1 (es)	2014-09-05	Compuestos inhibidores del virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vhc.